{
  "id": "5c6b7a9e7c78d69471000029",
  "type": "yesno",
  "question": "Is cabozantinib effective for Hepatocellular Carcinoma?",
  "ideal_answer": "Yes, cabozantinib is approved as second line agent for treatment of Hepatocellular Carcinoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27638856",
    "http://www.ncbi.nlm.nih.gov/pubmed/29505843",
    "http://www.ncbi.nlm.nih.gov/pubmed/29059635",
    "http://www.ncbi.nlm.nih.gov/pubmed/28426123",
    "http://www.ncbi.nlm.nih.gov/pubmed/30308081",
    "http://www.ncbi.nlm.nih.gov/pubmed/29283440",
    "http://www.ncbi.nlm.nih.gov/pubmed/30317696",
    "http://www.ncbi.nlm.nih.gov/pubmed/29807383",
    "http://www.ncbi.nlm.nih.gov/pubmed/30039640",
    "http://www.ncbi.nlm.nih.gov/pubmed/30087805",
    "http://www.ncbi.nlm.nih.gov/pubmed/29253194",
    "http://www.ncbi.nlm.nih.gov/pubmed/28703624",
    "http://www.ncbi.nlm.nih.gov/pubmed/29913090",
    "http://www.ncbi.nlm.nih.gov/pubmed/29783126",
    "http://www.ncbi.nlm.nih.gov/pubmed/24700742",
    "http://www.ncbi.nlm.nih.gov/pubmed/28862760",
    "http://www.ncbi.nlm.nih.gov/pubmed/29972759"
  ],
  "snippets": [
    {
      "text": "However, clinical trials of nonselective kinase inhibitors with c-Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28862760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29283440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, promising outcomes have also been reported with new agents, such as nivolumab and cabozantinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29253194",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29505843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29783126",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The rapidly changing treatment landscape due to the emergence of new treatment options (sorafenib and lenvatinib equally effective in first line; regorafenib, cabozantinib, and ramucirumab showing OS benefit in second line with nivolumab approved by the FDA based on response rate) underscores the importance of re-assessing the role of the first approved systemic agent in HCC, sorafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29783126",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Positive phase III-study data have been published for lenvatinib as first-line and cabozantinib as second-line therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29807383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Based on favorable phase III clinical trial data, sorafenib and lenvatinib are considered promising agents for HCC as first-line systemic chemotherapy. Moreover, regorafenib and cabozantinib are useful second-line therapies after the failure of sorafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29913090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo (hazard ratio for death, 0.76; 95% confidence interval [CI], 0.63 to 0.92; P=0.005). Median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.52; P<0.001), and the objective response rates were 4% and less than 1%, respectively (P=0.009).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most common high-grade events were palmar-plantar erythrodysesthesia (17% with cabozantinib vs. 0% with placebo), hypertension (16% vs. 2%), increased aspartate aminotransferase level (12% vs. 7%), fatigue (10% vs. 4%), and diarrhea (10% vs. 2%).<br><b>CONCLUSIONS</b>: Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972759",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS The tyrosine kinase inhibitors sorafenib (first line) and regorafenib (second line) have been approved for hepatocellular carcinoma, and the immune checkpoint inhibitor nivolumab obtained conditional approval for sorafenib-experienced patients in the United States.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The principal advancements in the treatment of hepatocellular carcinoma (HCC) are the use of new systemic treatments such as lenvatinib in first-line treatment and regorafenib, cabozantinib and ramucirumab in second-line treatment due to their benefits in terms of overall survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30317696",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, a few systemic chemotherapies proved to be effective for advanced stage HCC in phase III studies: lenvatinib as the first line of therapy, and regorafenib, cabozantinib, and ramucirumab as second-line therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30308081",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We also elaborate the unmet need of biomarkers to guide treatment decisions and discuss the emerging field of immunotherapy in hepatocellular carcinoma.<br><b>CONCLUSIONS</b>: The tyrosine kinase inhibitors sorafenib (first line) and regorafenib (second line) have been approved for hepatocellular carcinoma, and the immune checkpoint inhibitor nivolumab obtained conditional approval for sorafenib-experienced patients in the United States.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039640",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabozantinib in the treatment of hepatocellular carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28703624",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039640",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}